Figure 1From: A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthmaAverage daily symptom scores in (A) all subjects, (B) subjects with average pre-seasonal symptom score ≤ 3, and (C) subjects with average pre-seasonal symptom score >3. AIT = allergy immunotherapy tablet.Back to article page